

MATERIALS LICENSE

Amendment No. 47

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

"OFFICIAL RECORD COPY"

Licensee

1. Lynn Hospital
An Atlanticare Medical Center
2. 212 Boston Street
Lynn, Massachusetts 01904

In accordance with application dated
December 12, 1984,

3. License number 20-03339-02 is amended

in its entirety to read as follows:

4. Expiration date June 30, 1990

5. Docket or
Reference No. 030-018616. Byproduct, source, and/or
special nuclear material7. Chemical and/or physical
form8. Maximum amount that licensee
may possess at any one time
under this license

- A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35
- B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35
- C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35
- D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35
- E. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35
- F. Any byproduct material listed in Section 31.11(a) of 10 CFR 31

- A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35
- B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35
- C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35
- D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35
- E. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35
- F. Prepackaged kits

- A. As necessary for uses authorized in Subitem 6.A.
- B. 3 curies of each byproduct material authorized in Subitem 6.B.
- C. As necessary for uses authorized in Subitem 9.C.
- D. As necessary for uses authorized in Subitem 9.D.
- E. 1000 millicuries total for sources authorized in Subitem 6.E.
- F. 3 millicuries of each byproduct material authorized in Subitem 6.F.

8507050052 850617
REG1 LIC30
20-03339-02 PDR

ML10

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number

20-03339-02

Docket or Reference number

030-01861

Amendment No. 47

(continued)

G. Xenon 133

G. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA

G. 500 millicuries

H. Uranium (depleted in the isotope Uranium 235)

H. Cadmium plated metal

H. 250 kilograms

9. Authorized use

- A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations.
- B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- E. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- F. In vitro studies.
- G. Blood flow and pulmonary function studies.
- H. For use as shielding in a linear accelerator.

CONDITIONS

- 10. Licensed material shall be used only at the licensee's facilities, at 212 Boston Street, Lynn, Massachusetts 01904.
- 11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions, and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number

20-03339-02

Docket or Reference number

030-01861

Amendment No. 47

(Continued)

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Ferris J. Bargoot, M.D.

Groups I, II, III, IV, V and VI
In vitro studies
Xenon 133
Depleted Uranium as shielding

Herbert Leventhal, M.D.

Groups I, II, III, IV, V and VI
In vitro studies
Xenon 133
Depleted Uranium as shielding

Harry G. Olken, M.D.

Groups I, II, III, IV and V
In vitro studies
Xenon 133

Leonard Bouras, M.D.

Groups I, II, III and IV
In vitro studies
Xenon 133

Howard Rotner, M.D.

Groups I, II, III, IV and V
In vitro studies
Xenon 133

E. Mei Shen, M.D.

Groups I, II, III, IV and V
In vitro studies
Xenon 133

Polius Raslavicus, M.D.

Groups I, II, III, IV and V
In vitro studies
Xenon 133

Kenneth Bassion, M.D.

Groups I, II, III, IV and V
In vitro studies
Xenon 133

Dean Wasserman, M.D.

Groups I, II, III and IV
In vitro studies
Xenon 133

Harold Weintraub, M.D.

Groups I, II and III
In vitro studies
Xenon 133

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number

20-03339-02

Docket or Reference number

030-01861

Amendment No. 47

(Continued)

Magdi Christian Semine, M.D.

Groups I, II and III
In vitro studies
Xenon 133

Sheldon Cooperman, M.D.

Groups I, II and III
In vitro studies
Xenon 133
Iodine 131 for treatment of
hyperthyroidism and cardiac
dysfunction

Khalid M. Butt, M.D.

Groups I, II and III
In vitro studies
Xenon 133

13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.
14. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:
- (a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and
 - (b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and
 - (c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for the inspection by the Commission, copies of the written permission specified in subitem (a) above and of the license(s) specified in subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under subitem (a) above.

15. Sealed sources containing licensed material shall not be opened.
16. Patients containing Iodine 131 for the treatment of thyroid carcinoma shall remain hospitalized until the residual activity is 30 millicuries or less.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

20-03339-02

Docket or Reference number

030-01861

Amendment No. 47

(Continued)

17. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:
- A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.
 - B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
 - C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.
18. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated December 12, 1984, and letter dated May 17, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



For the U.S. Nuclear Regulatory Commission

Date JUN 17 1985

Original Signed By:
By John D. Kinneman
Nuclear Materials Safety and
Safeguards Branch, Region I
King of Prussia, Pennsylvania 19406